NCT04161014View on ClinicalTrials.gov

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

PHASE2UnknownINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions

Pneumoconiosis CoalAsbestosisSilicosis

Interventions

DRUG

Nintedanib 150 MG [Ofev]

Nintedanib 150mg twice daily for 3 years

Trial Locations (1)

2010

RECRUITING

Holdsworth House Medical Practice, Sydney

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Holdsworth House Medical Practice

OTHER

NCT04161014 - The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial | Biotech Hunter | Biotech Hunter